Small Doses Muscle Relaxant in General Anesthesia
This study will be held to assess the effect of minimal dose muscle relaxant on postoperative pulmonary function. The time to extubation in minutes will be the primary outcome as a clinical indicator of the return of muscle power. The extubation time will be defined as the time from injecting the muscle relaxant revers
| Condition(s) | Muscle Relaxant |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This study will be held to assess the effect of minimal dose muscle relaxant on postoperative pulmonary function. The time to extubation in minutes will be the primary outcome as a clinical indicator of the return of muscle power. The extubation time will be defined as the time from injecting the muscle relaxant reversing agent given when regain the train of four (TOF) ratio to 0.9 till removal of endotracheal tube. Intraoperative surgical conditions will be assessed in the form of surgeon satisfaction and the need for more muscle relaxant boluses. Postoperative complications as desaturation (peripheral oxygen saturation (Spo2) less than 90%), the need for re-intubation or ventilation support will be recorded. Patient lung will be assessed using ultrasound-based lung aeration score. Also, |
| Who can participate | Inclusion Criteria: * adult patients * aged from 20 to 50 years old * scheduled for non-cardiothoracic surgery * under general anesthesia * in supine position * after informed consent Exclusion Criteria: * American Society of Anesthesiologists (ASA) score more than 3 * suspected full stomach or who will undergo intervention expected to necessitate profound muscle relaxation or dressing interferes with ultrasound (US) probe positioning * Lung parenchymatous disease * renal disease * hepatic disease * neuromuscular disease * electrolytes imbalanc * on medication interfere with muscle contraction * with known allergy to any drug used in the study |
| Ages | 20 Years to 50 Years |
| Sex | All |
| Lead sponsor | Mansoura University |
| Locations | Al Mansurah, Egypt |
| Start date | 2020-04-22 |
| NCT ID | NCT04344262 |
| Official listing | https://clinicaltrials.gov/study/NCT04344262 |